Krystal Biotech (KRYS) Q4 2025 earnings review
International Launch Drives Revenue Acceleration
Krystal Biotech closed FY25 with a strong acceleration in revenue, posting $107.1M in Q4 (up 9.5% sequentially from $97.8M in Q3). The growth narrative has successfully pivoted to international markets, with over 90 patients now on therapy across Germany, France, and Japan. Profitability remains robust with $51.4M in Net Income (48% net margin) and a fortress balance sheet of $956M. While US growth appears to be moderating as the company works through the patient funnel, the pipeline provided a secondary boost to the thesis with positive CF data and RMAT designation for Oncology.
🐂 Bull Case
The ex-US launch is ramping faster than anticipated. Patient count jumped from ~20 in Q3 (Germany only) to over 90 in Q4 (Germany, France, Japan). Israel distribution added. This validates the global demand for VYJUVEK.
The company is de-risking beyond a single asset. Positive Phase 1 data for KB407 (Cystic Fibrosis) confirmed lung delivery, and FDA granted RMAT designation to KB707 (Oncology), speeding up the regulatory pathway.
🐻 Bear Case
Total revenue grew $9.3M QoQ. Given the addition of ~70 international patients in the quarter, implied US revenue is likely flat or slightly down. The US market is entering the 'harder yards' of penetration.
Pricing talks in France are now expected to last until at least 2027, and Germany until 2H 2026. While access is open, final pricing stability is delayed, extending the period of commercial uncertainty in key EU markets.
⚖️ Verdict: 🟢🟢
Strong Bullish. Revenue re-accelerated to double-digit sequential growth thanks to international execution. With nearly $1B in cash and a profitable base business funding a high-potential pipeline (CF/Oncology), KRYS is executing flawlessly.
Key Themes
International Market Ramp
Accelerating. The ex-US story is now the primary growth engine. Patient count surged to >90 (from ~20 in Q3). Markets are active in Germany, France, and Japan. A new distribution deal for Israel signals further expansion. This rapid uptake compensates for the natural maturation of the US market.
Spending Acceleration
Operating expenses are set to rise. FY26 guidance for Non-GAAP R&D and SG&A is $175-$195M. This compares to implied FY25 Non-GAAP spend of ~$155M (derived from prior guidance). The company is investing heavily in the pipeline (CF, Oncology) and global commercial infrastructure, which will temper near-term margin expansion.
Oncology & Respiratory Pipeline Validation
Two major wins for the platform: 1) KB407 (CF) showed broad airway distribution (29-42% of cells) in a Phase 1 study, validating the inhaled delivery mechanism. 2) KB707 (Lung Cancer) received FDA RMAT designation, which typically expedites development and review. This shifts the narrative from a 'single-product dermatology company' to a 'platform gene therapy' play.
US Reimbursement Velocity
Decelerating. US reimbursement approvals reached 'over 660' in Q4, up from 'over 615' in Q3 (+45 adds) and 'over 575' in Q2 (+40 adds). While growing, the pace is steady rather than explosive, confirming that the initial bolus of pent-up US demand has been processed.
Cash Accumulation
Cash generation is relentless. Cash and investments hit $955.9M, up from $864M in Q3. The company added ~$92M in liquidity in a single quarter. This provides immense optionality for M&A or massive buybacks, though management has not yet committed to capital returns.
Other KPIs
Stable. Margins remain elite at 94% (vs 96% in Q3 and 93% in Q2). The slight dip from Q3 reflects the mix shift toward international markets, which may have different transfer pricing or manufacturing cost dynamics, but remains well above industry averages.
Accelerating. Full year EPS more than doubled from $3.00 in FY24. The business model is demonstrating exceptional operating leverage, even with R&D spend ramping up.
Stable relative to revenue. COGS increased only $1.6M YoY despite a $16M increase in revenue, confirming the scalability of the HSV-1 manufacturing platform.
Guidance
Accelerating. This represents a ~20% increase over the FY25 guide ($145-155M). Reasons cited include multiple registrational study starts (HHD, Oncology) and continued global commercial expansion.
Accelerating. Following positive Phase 1 data, the company is moving directly to a repeat-dosing study intended to support registration. Alignment with FDA on design is expected in 1H 26.
Decelerating/Delayed. Previously expected to continue 'at least 15 months' from Nov 2025, now explicitly stated to continue 'until at least 2027'. Revenue will continue under early access, but final price certainty is pushed out.
Key Questions
US vs International Split
With ~70 patients added internationally and a $9.3M sequential revenue lift, it implies US revenue was flat to down. Can you explicitly break out US revenue trends to confirm if the domestic market has plateaued?
Cash Deployment Strategy
You are approaching $1B in cash with a profitable business. Beyond the pipeline spend, do you plan to authorize a share buyback or look for external asset acquisition?
Gross Margin Sustainability
As the mix shifts heavily toward ex-US markets (where you've noted lower pricing or different manufacturing costs previously), should we model gross margins compressing below the current 94% level in FY26?